SecBot SecBot
SECBOTREPLAY Home › Report › ARGX

ARGX · argenx announced a definitive agreement to acquire Forte Biosciences…

ARGENX SE · 6-K filed Jul 27, 2026 at 06:03 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jul 27, 2026 at 06:03 ET

argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a total equity value of approximately $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The acquisition, funded entirely from cash on hand and expected to close in Q3 2026, provides argenx with a pipeline-in-a-product opportunity with clinical proof-of-concept in vitiligo and celiac disease, broadening its portfolio beyond FcRn biology into T-cell and NK-cell mediated autoimmune diseases. The deal represents a strategic bolt-on that strengthens argenx's long-term growth narrative without diluting shareholders or adding debt.

  • argenx to acquire Forte Biosciences for $77 per share in cash, total equity value of approximately $2.2 billion.
  • The acquisition adds FB102, a first-in-class anti-CD122 antibody with Phase 1b proof-of-concept in vitiligo and celiac disease.
  • Transaction is not subject to a financing condition and will be funded entirely from cash on hand.
  • Acquisition expected to close in Q3 2026, subject to customary conditions including HSR clearance.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access